Skip to main content
European Commission logo
Enterprise Europe Network

AI-driven biotech for in silico drug design (protein and chemical drugs) to accelerate drug discovery


Profile Type
Technology offer
POD Reference
Term of Validity
15 May 2023 - 14 May 2024
Company's Country
South Korea
Type of partnership
Investment agreementResearch and development cooperation agreement
Targeted Countries
All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
The company is a venture capital-backed company located in South Korea, and they are seeking a partner with drug development expertise to develop innovative drugs by leveraging its AI-enabled drug design platforms.
Full Description
The company is an AI-enabled biotechnology company that harnesses the power of AI to design highly targeted drugs. Their main objective is to develop an AI-enabled protein drug design platform, including antibodies, cytokines, and other protein therapies. Their aim is to create a paradigm shift in the early drug development process, shifting from a trial & error-based approach to a calculation & prediction-based process. By eliminating uncertainties and guesswork from the process, they can improve the efficiency and effectiveness of early drug development.

Some examples of BioDesign platform’s current application include:
A. Affinity modulation (enhancement and reduction) of a protein drug. In case of a protein compound with multiple natural binding partners, it is possible to improve affinity towards select binding partner(s) while decreasing affinity towards the other(s).
B. pH-dependent affinity modulation of a protein drug. In the context of anti-cancer therapeutics, this type of modulation can lead to a compound that exclusively binds to its target only in an acidic environment like that of a tumor-microenvironment.
C. Fc engineering of an antibody to selectively activate antibody's effector function(s).

In addition, they are currently working towards their next milestone for the platform: iESA and iFcab.
>> iESA (in silico epitope-specific antibody) will enable the design of an antibody that can bind to a specific epitope or area of a molecular target, the generation of antibodies that can discern targets with high homology, and raise antibodies against a target that have traditionally resisted antibody discovery endeavors using conventional laboratory techniques.
>> iFcab (in silico epitope-specific Fc antigen binding) will enable the modulation of the Fc region of an antibody to function similarly to that of the Fab region of an antibody (antigen binding) without sacrificing any of the antibody's effector functions. This type of modulation would allow the generation of unconventional bi-specific antibodies and tri-specific antibodies.
Advantages and Innovations
The company is a young company with a strong foundation of proven success and their foundational technology has been in development since the year 2000 when its CEO, Dr. Seok, started working on molecular modeling software called Galaxy SW.

Over the years, Galaxy has gained international recognition as one of the leading solutions in predicting molecular structure and interaction, earning top spots at a global competition like CASP (evaluates the accuracy of predicted protein structure) and CAPRI (evaluates the accuracy of predicted protein-protein interaction). Global companies, like DeepMind (Google), Microsoft, and Tencent, participate in these competitions to showcase their molecular structure and interaction prediction technologies.

The company was founded on the backbone of Galaxy SW to enhance it further and to integrate artificial intelligence. Their approach has demonstrated significantly higher success rate of accurate prediction of structure/interaction compared to other notable approaches in the industry.
Stage of Development
Available for demonstration
Sustainable Development Goals
Goal 17: Partnerships to achieve the GoalGoal 8: Decent Work and Economic GrowthGoal 3: Good Health and Well-being

Partner Sought

Expected Role of a Partner
They are seeking a partner with drug development expertise and they envision dual approach for collaboration:

1. Practical collaboration.
>> This would entail leveraging their platform's current capabilities, particularly BioDesign's affinity modulation, pH-dependent affinity modulation, and Fc engineering capabilities to enhance the characteristics of protein drugs.

Starting with the practical collaboration would allow the partner company the opportunity to experience what they can bring to the table and assess the compatibility between the two firms.

2. Innovative collaboration.
>> This would involve designing innovative protein therapeutics against challenging targets, such as GPCRs.
Type and Size of Partner
SME 11-49
Type of partnership
Investment agreementResearch and development cooperation agreement

Call details

Coordinator required


Technology keywords
01004001 - Applications for Health06001002 - Clinical Research, Trials06001012 - Medical Research06002009 - Molecular design06002004 - Protein Engineering
Market keywords
02007017 - Expert systems02007007 - Applications software02007012 - Medical/health software04005 - Biochemistry / Biophysics02006009 - Other computer services
Targeted countries
All countries